% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Koerber:127604,
      author       = {S. A. Koerber$^*$ and A. Slynko$^*$ and M. F. Haefner and
                      D. Krug and C. Schoneweg and K. Kessel and A.
                      Kopp-Schneider$^*$ and K. Herfarth and J. Debus$^*$ and F.
                      Sterzing$^*$},
      title        = {{E}fficacy and toxicity of chemoradiation in patients with
                      anal cancer--a retrospective analysis.},
      journal      = {Radiation oncology},
      volume       = {9},
      number       = {1},
      issn         = {1748-717X},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2017-03627},
      pages        = {113},
      year         = {2014},
      abstract     = {Concurrent chemotherapy and radiation therapy is the
                      preferred standard of care for patients with anal cancer.
                      Several studies have suggested a benefit of
                      intensity-modulated radiation therapy (IMRT) compared with
                      3D-conformal radiation (3D-CRT) regarding acute toxicity.
                      This study evaluates outcome and toxicity of patients
                      undergoing IMRT/Tomotherapy or 3D-CRT at our institution.A
                      cohort of 105 anal cancer patients was treated with
                      chemoradiation or radiation alone $(16.2\%)$ between January
                      2000 and December 2011. 37 patients received 3D-CRT while 68
                      patients were treated with IMRT. Follow-up exams were
                      performed every 3 to 6 months for a minimum of 3 years and
                      then annually.Median follow-up was 41.4 months (2.8 -
                      158.4). Overall survival (OS), Progression-free survival
                      (PFS) and local control (LC) at 3 years was $70.3\%,$
                      $66.5\%,$ $78.3\%$ in the 3D-CRT group and $82.9\%,$
                      $66.5\%,$ $75.3\%$ in the IMRT group without statistically
                      significant difference. 3-year Colostomy-free survival (CFS)
                      was $85.7\%$ in the IMRT/Tomotherapy group and $91.8\%$ in
                      the 3D-CRT group (p = 0.48). No grade 4 toxicity was
                      found in both groups. Severe (G2/3) acute skin toxicity
                      $(94.6\%$ vs. $63.2\%;$ p < 0.001) and acute
                      gastrointestinal toxicity rate $(67.6\%$ vs. $47.1\%;$
                      p = 0.03) was significantly higher with 3D-CRT compared
                      to IMRT/Tomotherapy.The use of IMRT can reduce acute severe
                      side effects of the skin and gastrointestinal tract but did
                      not demonstrate improved results regarding OS, PFS, LC and
                      CFS.},
      cin          = {C060 / E050},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)E050-20160331},
      pnm          = {315 - Imaging and radiooncology (POF3-315)},
      pid          = {G:(DE-HGF)POF3-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:24886574},
      pmc          = {pmc:PMC4030022},
      doi          = {10.1186/1748-717X-9-113},
      url          = {https://inrepo02.dkfz.de/record/127604},
}